SEC Form 4 · accession 0001128732-16-000025
Sunshine Biopharma Inc. · SBFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve N. Slilaty
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Jul 8, 2016
Accepted (ET)
Aug 1, 2016 · 11:35 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001402328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2016 | J | 321,305,416 | $0.0026 | A | 351,876,192 | I | Owned by Advanomics Corporation, an entity controlled by Reporting Person. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Issuer issued 321,305,416 shares of its Common Stock to Advanomics Corporation, a related party, in consideration for cancellation of two promissory notes payable to Advanomics Corporation in the aggregate amount of $835,394.